Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Rating of Russian Pharmaceutical Distributors (Q1-Q3 2018)

Monday, November 12, 2018

Between January and September 2018, there was not any major changes in the ranking of the top pharmaceutical distributors, except for the top places. The first three places have changed, with Puls having reached first place after quite a struggle. The changes are not that surprising, which we discussed in our previous review (Q1 – Q2 results).

The market is still undergoing consolidation, with the share of the largest companies having increased by 2.8% over the year. Only our distributors have had their market share decreased, however, Protek and Katren have done it deliberately to clean their client’s portfolio. R-Pharm is also doing better; its subsidiary R-Opra won a tender for the right to conclude a second offset contract with Moscow. Even the fate of the long-suffering SIA International has more or less been determined; in October, the board of Magnit approved the purchase of it. Moreover, despite the transaction not having been closed yet, Magnit has already begun negotiations with manufacturers, for which they bought an operating company with a license for pharmaceutical activity in September.

We should also mention the hot initiative by Andrei Belousov, Assistant to the Russian President, who proposed to form a united pharmaceutical drug importer, able to consolidate the import of pharmaceuticals and medical devices amounting to 200 bln RUB a year. Well, let us see.

Tab 1. Top 15 pharmaceutical distributors with the largest market share of direct shipments of drugs (including preferential shipments), in monetary terms (Q1-Q3 2018)